Bioequivalence of a Liquid Formulation of Alpha1-Proteinase Inhibitor Compared with Prolastin®-C (Lyophilized Alpha1-PI) in Alpha1-Antitrypsin Deficiency

Overview of attention for article published in COPD: Journal of Chronic Obstructive Pulmonary Disease, October 2017

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (66th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

policy: 1 policy source
twitter: 1 X user

facebook: 1 Facebook page

Readers on

mendeley: 27 Mendeley

So far, Altmetric has seen 1 policy document that references this research output.

Prolastin-C for the Treatment of Alpha1-Antitrypsin Deficiency: A Review of Clinical and Cost-Effectiveness

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 12 Apr 2019

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.